Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Athera signs collaboration agreement with Dyax
During the discovery phase of the collaboration, Dyax will utilize its proprietary antibody libraries to generate fully human monoclonal antibodies. Athera will provide reagents, assays, and in vivo
During the discovery phase of the collaboration, Dyax will utilize its proprietary antibody libraries to generate fully human monoclonal antibodies. Athera will provide reagents, assays, and in vivo
The decision to enter the second stage of patient recruitment was taken following recent first stage data reporting two partial responses among patients with a diagnosis of platinum-resistant
The financing was led by Lilly Ventures with participation from other new investors, Roche Venture Fund and MP Healthcare Venture Management. Existing investors, Frazier Healthcare Ventures, Alta Partners,
John Amatruda, senior vice president and research head of diabetes and obesity at Merck Research Laboratories, said: “Available Phase III data showed that both efficacy and adverse events
According to the news source, ImClone has refused to comment on the proposed deal but has divulged that it is in talks with a big pharma company. ImClone
The Phase IIa clinical trial, OZ-101, is designed to examine the effectiveness of OREX-003 in mitigating drug-associated weight gain or other metabolic consequences commonly experienced by patients taking
Identity 2 is expected to enroll 1,100 patients, and includes a treatment period of approximately 21 months. An open-label extension will be available to all participants completing the
This DPP HIV 1-2 rapid test has been developed by Chembio with its patented Dual Path Platform technology. Oswaldo Cruz Foundation of Brazil (Fiocruz), which is affiliated with
The administrative and civil settlement agreements also resolve all US Drug Enforcement Administration (DEA) claims related to the company’s controls against the diversion of controlled substances. Without admitting
The transaction was completed on October 1, 2008. The transaction will be financed from existing cash balances and available lines of credit. Upon closing, Hill-Rom expects to benefit